EDMONTON, Alberta, March 6 /PRNewswire-FirstCall/ -- In October, 2006, Medical Services International Inc (OTC:MSITF) announced that it was beginning to ship VScan TB rapid test kits To South Africa. At the request of its distributor and as a result of thousands of infected people being sent back to their communities because of inadequate testing methods the Company has been asked to accelerate the VScan testing program. Current testing -- a standard smear sputum test failed to diagnose the disease resulting in misdiagnosed, infected people spreading TB unknowingly in their communities. Specialists have indicated that 60% of the TB cases in South Africa are smear negative (not detected on a sputum test). The VScan TB rapid test kit can be used to diagnose smear negative TB test cases. The VScan TB test kit is the only rapid test kit with this capability. Smear negative TB is more common in people living with HIV A report released by the Treatment Action Campaign said South Africa not only had one of the highest HIV/AIDS rates in the world but also one of the highest incidence rates for TB and this was increasing drastically as the HIV epidemic worsened. Of the estimated 9 million people who develop active TB every year, most still do not receive a laboratory confirmed diagnosis. Tuberculosis (TB) is highly contagious. Once the testing of the VScan TB test kit is completed in the next 60 days, the Company expects to sell in excess of 1.0 million TB test kits per year. This will generate over $3.0 million in gross revenue. About VScan The VScan rapid test kit is a single use, easy to use, test for the screening of HIV1&2, Hepatitis B&C, Tuberculosis (TB), Dengue Fever, Malaria, West Nile, Syphilis and Prostate Cancer. The kits cannot be sold in Canada. Medical Services International Inc trades in the United States on the NQB Pinksheets under the symbol "MSITF". For further information, please contact Robert Talbot at (780) 430 6363 or http://www.medicalservicesintl.com/ or http://www.minerva-biotech.com/ . NOTE: Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that may cause results to differ materially. Such risks, uncertainties and other factors include but are not limited to new economic conditions, risk in product development, market acceptance of new products and other factors described in Company reports and other filings with regulatory bodies. DATASOURCE: Medical Services International Inc CONTACT: Robert Talbot, Medical Services International Inc, +1-780-430-6363 Web site: http://www.medicalservicesintl.com/ http://www.minerva-biotech.com/

Copyright